Cargando…
Cancer pharmacology and pharmacotherapy review : study guide for oncology boards and MOC exams /
Cancer Pharmacology and Pharmacotherapy Review is the first book devoted entirely to providing the 'must-know' facts on each cancer agent including their pharmacokinetics, FDA-approved indications, toxicity, interactions, and other important information that is commonly found on board exam...
| Clasificación: | Libro Electrónico |
|---|---|
| Autores principales: | , , |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York :
Demos Medical,
[2016]
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | EBSCO_ocn942588609 | ||
| 003 | OCoLC | ||
| 005 | 20231017213018.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 160302s2016 nyua o 001 0 eng d | ||
| 040 | |a N$T |b eng |e rda |e pn |c N$T |d IDEBK |d YDXCP |d N$T |d OCLCQ |d CDX |d OCLCF |d EBLCP |d USU |d OCLCQ |d VT2 |d OCLCO |d OCLCQ |d OCLCO | ||
| 066 | |c (S | ||
| 019 | |a 946309732 |a 1235840107 | ||
| 020 | |a 9781617052521 |q (electronic bk.) | ||
| 020 | |a 1617052523 |q (electronic bk.) | ||
| 020 | |z 9781620700761 | ||
| 020 | |a 162070076X | ||
| 020 | |a 9781620700761 | ||
| 029 | 1 | |a AU@ |b 000062358482 | |
| 035 | |a (OCoLC)942588609 |z (OCoLC)946309732 |z (OCoLC)1235840107 | ||
| 050 | 4 | |a RS431.A64 | |
| 060 | 4 | |a QV 18.2 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 0 | 4 | |a 615.7/98076 |2 23 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Worden, Francis P., |e author. | |
| 245 | 1 | 0 | |a Cancer pharmacology and pharmacotherapy review : |b study guide for oncology boards and MOC exams / |c Francis P. Worden, Anthony J. Perissinotti, Bernard L. Marini. |
| 264 | 1 | |a New York : |b Demos Medical, |c [2016] | |
| 300 | |a 1 online resource (xiv, 189 pages) : |b color illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Online resource; title from PDF title page (EBSCO, viewed March 8, 2016). | |
| 500 | |a Includes index. | ||
| 520 | |a Cancer Pharmacology and Pharmacotherapy Review is the first book devoted entirely to providing the 'must-know' facts on each cancer agent including their pharmacokinetics, FDA-approved indications, toxicity, interactions, and other important information that is commonly found on board examinations and essential for any clinician or practitioner to review . The authors, an oncologist and two pharmacists, have developed a handy question-and-answer format to present the material in digestible bursts. As the pharmacology section continues to represent a major portion of the medical oncology exam and a key component on oncology MOC exams, this portable study guide will help prepare anyone looking to fine-tune their knowledge on cancer drugs before the test. Not to mention, with recent advancements in the field of cancer treatment, it has become more cumbersome to recall and maintain essential knowledge of every cancer therapeuticómaking this book not only an exam resource but also a handy quick reference for oncologists and pharmacists alike. Key Features: Conveniently organized and arranged by drug class and subtypes for easier recall and classification Includes proper dosage adjustments to account for liver and kidney dysfunction. Features tables throughout that provide quick reference regarding FDA-approved medications Simplified diagrams and illustrations facilitate the pharmacokinetic processes. | ||
| 505 | 0 | |a Cover; Title; Copyright; Contents; List of Figures; List of Tables; Preface; Share Cancer Pharmacology and Pharmacotherapy Review: Study Guide for Oncology Boards and MOC Exams; Part I: Traditional Chemotherapy; Chapter 1: Microtubule Inhibitors; Taxanes and Related Agents; Vinca Alkaloids; Chapter 2: Alkylating Agents; Nitrogen Mustards; Non-Nitrogen Mustards; Platinums; Antitumor Antibiotics; Chapter 3: Enzyme Inhibitors-Topoisomerase I Inhibitors; Camptothecans; Chapter 4: Enzyme Inhibitors-Topoisomerase II Inhibitors; Epipodophyllotoxins; Anthracyclines; Chapter 5: Antimetabolites | |
| 505 | 8 | |a AntifolatesPurine Antagonists; Purine Analogues; Pyrimidine Analogues/Fluoropyrimidines; Pyrimidine Analogues/Deoxycytidine Analogues; Part II: Next-Generation Antineoplastics; Chapter 6: Monoclonal Antibodies; Chapter 7: VEGF Trap; Ziv-Aflibercept (Zaltrap®); Chapter 8: Tyrosine Kinase Inhibitors; Angiogenesis Inhibitors and Multi-Kinase Inhibitors; Breakpoint Cluster Region-Abelson Murine Leukemia Viral Oncogene Homolog 1 (BCR-ABL) Inhibitors; B-Cell Receptor (BCR) Pathway Inhibitors; EGFR-Ras-Raf-MEK-ERK (MAPK) Pathway Inhibitors; Miscellaneous Oral Targeted Therapies | |
| 505 | 8 | |6 880-01 |a Appendix A: Agents Requiring Renal and/or Hepatic Dose AdjustmentsAppendix B: Extravasation Risk of Chemotherapeutic Agents; Index | |
| 590 | |a eBooks on EBSCOhost |b EBSCO eBook Subscription Academic Collection - Worldwide | ||
| 650 | 0 | |a Antineoplastic agents |x Physiological effect |v Problems, exercises, etc. | |
| 650 | 0 | |a Tumors |x Chemotherapy |v Problems, exercises, etc. | |
| 650 | 2 | |a Antineoplastic Agents |x pharmacology | |
| 650 | 2 | |a Neoplasms |x drug therapy | |
| 650 | 6 | |a Anticancéreux |x Effets physiologiques |v Problèmes et exercices. | |
| 650 | 6 | |a Tumeurs |x Chimiothérapie |v Problèmes et exercices. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Antineoplastic agents |x Physiological effect |2 fast | |
| 650 | 7 | |a Tumors |x Chemotherapy |2 fast | |
| 655 | 2 | |a Examination Questions | |
| 655 | 2 | |a Problems and Exercises | |
| 655 | 7 | |a exercise books. |2 aat | |
| 655 | 7 | |a Problems and exercises |2 fast | |
| 655 | 7 | |a Problems and exercises. |2 lcgft | |
| 655 | 7 | |a Problèmes et exercices. |2 rvmgf | |
| 700 | 1 | |a Perissinotti, Anthony J., |e author. | |
| 700 | 1 | |a Marini, Bernard L., |e author. | |
| 776 | 0 | 8 | |i Print version: |a Worden, Francis P., MD. |t Cancer Pharmacology and Pharmacotherapy Review : Study Guide for Oncology Boards and MOC Exams. |d : Springer Publishing Company, ©2016 |z 9781620700761 |w (DLC) 2015045238 |w (OCoLC)930576198 |
| 856 | 4 | 0 | |u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1193410 |z Texto completo |
| 880 | 8 | |6 505-01/(S |a Chapter 9: Antiandrogen TherapiesChapter 10: Mammalian Target of Rapamycin (mTOR) Inhibitors; Chapter 11: Histone Deacetylase (HDAC) Inhibitors; Chapter 12: Hypomethylating Agents; Chapter 13: Proteasome Inhibitors; Chapter 14: Immunomodulatory Agents; Chapter 15: L-Asparaginase Enzymes; Chapter 16: Promyelocytic Leukemia Gene Retinoic Acid Receptor-Alpha (PML-RARα) Translocation Inhibitors; Part III: Miscellaneous Oncolytics; Chapter 17: Sipuleucel-T (Provenge®); Chapter 18: Omacetaxine (Synribo®); Chapter 19: Estramustine (Emcyt®) | |
| 938 | |a EBSCOhost |b EBSC |n 1193410 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n cis34101607 | ||
| 938 | |a YBP Library Services |b YANK |n 12872620 | ||
| 938 | |a Coutts Information Services |b COUT |n 34101607 | ||
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL4428049 | ||
| 994 | |a 92 |b IZTAP | ||